t-cell-malignancies
(2)
The $350 Million Bet on Turning Down an Immune Fire
Electra Therapeutics is testing whether a precise antibody can quiet a deadly inflammatory spiral by removing the cells that feed it. A tiny early trial opened the door; a public offering has made the next test much larger.
Wugen
Wugen is a clinical-stage biotechnology company in St. Louis engineering off-the-shelf, allogeneic cell therapies for cancer. Spun out of Washington University in St. Louis in 2018, it builds CRISPR-edited CAR-T cells and cytokine-induced memory NK cells designed to be manufactured once from healthy donors and delivered to many patients. Its lead program, WU-CART-007 (soficabtagene geleucel), is a CD7-targeted allogeneic CAR-T in a pivotal trial for relapsed/refractory T-cell leukemia and lymphoma, carrying FDA Breakthrough Therapy, RMAT, Fast Track, Orphan Drug and Rare Pediatric Disease designations.